Fibroblast-like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin-11
Sook Kyung Chang,
Zhizhan Gu,
Michael B. Brenner,
Sook Kyung Chang
Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Havard Medical School, Boston, MA, USA.
Search for more papers by this authorZhizhan Gu
Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Havard Medical School, Boston, MA, USA.
Search for more papers by this authorMichael B. Brenner
Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Havard Medical School, Boston, MA, USA.
Search for more papers by this authorSook Kyung Chang,
Zhizhan Gu,
Michael B. Brenner,
Sook Kyung Chang
Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Havard Medical School, Boston, MA, USA.
Search for more papers by this authorZhizhan Gu
Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Havard Medical School, Boston, MA, USA.
Search for more papers by this authorMichael B. Brenner
Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Havard Medical School, Boston, MA, USA.
Search for more papers by this authorMichael B. Brenner
Theodore B. Bayles Professor of Medicine, Harvard Medical School Chief, Division of Rheumatology, Immunology and Allergy Brigham and Women’s Hospital, BostonSmith Building, Room 552One Jimmy Fund WayBoston, MA 02115, USA.Tel.: +1 617 525 1000Fax: +1 617 525 1001e-mail: [email protected]
Abstract
Summary: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting the joint synovium. The normal synovium consists of a lining layer of fibroblast-like synoviocytes (FLS) and macrophages, one to three cells deep that overlies the loose connective tissue of the synovial sublining. During the course of RA, the synovium is the site of inflammation where immune cells are massively infiltrated, and the lining layer becomes hyperplastic and transforms into a pannus tissue that destroys articular cartilage and bone. FLS play an important role in this RA pathogenesis. In this review, we explain that cadherin-11, an adhesion molecule, is selectively expressed on FLS and required for synovial lining formation. In addition, cadherin-11 on FLS contributes to synovial inflammation and mediates cartilage degradation in a mouse model of inflammatory arthritis. Therefore, we suggest that FLS are critical regulators of synovial inflammation and arthritis pathology via mechanisms that are mediated by cadherin-11.
References
- 1 Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev 2008; 223: 252–270.
- 2 Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356–361.
- 3 Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397–440.
- 4 Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005; 204: 55–73.
- 5 Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16: 180–185.
- 6 Fiocco U, et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmune Rev 2008; 8: 76–82.
- 7 Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008; 41: 84–91.
- 8 Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 296–301.
- 9 Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041–1045.
- 10
Chu CQ,
Field M,
Feldmann M,
Maini RN.
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis.
Arthritis Rheum
1991; 34: 1125–1132.
10.1002/art.1780340908 Google Scholar
- 11 Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7–19.
- 12 Peters PM, et al. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol 1986; 137: 2592–2598.
- 13 Kinkhabwala M, et al. A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med 1990; 171: 941–946.
- 14 Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990; 346: 274–276.
- 15 O’Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Natl Rev 2002; 2: 37–45.
- 16 Keffer J, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025–4031.
- 17 Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992; 89: 7375–7379.
- 18 Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510–514.
- 19 Maini R, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–1939.
- 20 Lipsky PE, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–1602.
- 21 Maini RN, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051–1065.
- 22 Klareskog L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675–681.
- 23 Breedveld FC, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37.
- 24 Joosten LA, Helsen MM, Van De Loo FA, Van Den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39: 797–809.
- 25 Horai R, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313–320.
- 26 Niki Y, et al. Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest 2001; 107: 1127–1135.
- 27 Joosten LA, Helsen MM, Saxne T, Van De Loo FA, Heinegard D, Van Den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049–5055.
- 28 Hirano T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73–76.
- 29 Teranishi T, Hirano T, Arima N, Onoue K. Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor- (TRF) like factor(s). J Immunol 1982; 128: 1903–1908.
- 30 Kishimoto T. Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol 2005; 23: 1–21.
- 31 Uson J, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997; 24: 2069–2075.
- 32 Wood NC, Symons JA, Dickens E, Duff GW. In situ hybridization of IL-6 in rheumatoid arthritis. Clin Exp Rheumatol 1992; 87: 183–189.
- 33 Houssiau FA, Devogelaer JP, Van Damme J, De Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784–788.
- 34 Hirano T, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18: 1797–1801.
- 35 Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232–234.
- 36 Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989; 83: 585–592.
- 37 Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1096–1105.
- 38 Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995; 34: 321–325.
- 39 Atsumi T, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002; 196: 979–990.
- 40 Nowell MA, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003; 171: 3202–3209.
- 41 Takagi N, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998; 41: 2117–2121.
- 42 Alonzi T, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461–468.
- 43 Choy EH, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143–3150.
- 44 Nishimoto N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761–1769.
- 45 Maini RN, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817–2829.
- 46 Genovese MC, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968–2980.
- 47 Revell PA, Al-Saffar N, Fish S, Osei D. Extracellular matrix of the synovial intimal cell layer. Ann Rheum Dis 1995; 54: 404–407.
- 48 Waggett AD, Kielty CM, Shuttleworth CA. Microfibrillar elements in the synovial joint: presence of type VI collagen and fibrillin-containing microfibrils. Ann Rheum Dis 1993; 52: 449–453.
- 49 Worrall JG, Wilkinson LS, Bayliss MT, Edwards JC. Zonal distribution of chondroitin-4-sulphate/dermatan sulphate and chondroitin-6-sulphate in normal and diseased human synovium. Ann Rheum Dis 1994; 53: 35–38.
- 50 Yielding KL, Tomkins GM, Bunim JJ. Synthesis of hyaluronic acid by human synovial tissue slices. Science 1957; 125: 1300.
- 51 Iwanaga T, Shikichi M, Kitamura H, Yanase H, Nozawa-Inoue K. Morphology and functional roles of synoviocytes in the joint. Arch Histol Cytol 2000; 63: 17–31.
- 52 Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005; 115: 118–128.
- 53 Barland P, Novikoff AB, Hamerman D. Electron microscopy of the human synovial membrane. J Cell Biol 1962; 14: 207–220.
- 54 Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451–1455.
- 55 Tanihara H, Sano K, Heimark RL, St John T, Suzuki S. Cloning of five human cadherins clarifies characteristic features of cadherin extracellular domain and provides further evidence for two structurally different types of cadherin. Cell Adhesion Commun 1994; 2: 15–26.
- 56 Kimura Y, et al. Cadherin-11 expressed in association with mesenchymal morphogenesis in the head, somite, and limb bud of early mouse embryos. Dev Biol 1995; 169: 347–358.
- 57 Hoffmann I, Balling R. Cloning and expression analysis of a novel mesodermally expressed cadherin. Dev Biol 1995; 169: 337–346.
- 58 Price SR, De Marco Garcia NV, Ranscht B, Jessell TM. Regulation of motor neuron pool sorting by differential expression of type II cadherins. Cell 2002; 109: 205–216.
- 59 Niessen CM, Gumbiner BM. Cadherin-mediated cell sorting not determined by binding or adhesion specificity. J Cell Biol 2002; 156: 389–399.
- 60 Duguay D, Foty RA, Steinberg MS. Cadherin-mediated cell adhesion and tissue segregation: qualitative and quantitative determinants. Dev Biol 2003; 253: 309–323.
- 61 Patel SD, Chen CP, Bahna F, Honig B, Shapiro L. Cadherin-mediated cell-cell adhesion: sticking together as a family. Curr Opin Struct Biol 2003; 13: 690–698.
- 62 Kawaguchi J, et al. Targeted disruption of cadherin-11 leads to a reduction in bone density in calvaria and long bone metaphyses. J Bone Miner Res 2001; 16: 1265–1271.
- 63 Okazaki M, et al. Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts. J Biol Chem 1994; 269: 092–098.
- 64 Kawaguchi J, Takeshita S, Kashima T, Imai T, Machinami R, Kudo A. Expression and function of the splice variant of the human cadherin-11 gene in subordination to intact cadherin-11. J Bone Miner Res 1999; 14: 764–775.
- 65 Shibata T, Ochiai A, Gotoh M, Machinami R, Hirohashi S. Simultaneous expression of cadherin-11 in signet-ring cell carcinoma and stromal cells of diffuse-type gastric cancer. Cancer Lett 1996; 99: 147–153.
- 66 Valencia X, et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med 2004; 200: 1673–1679.
- 67 Tomita K, et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000; 60: 3650–3654.
- 68
Markus MA, et al.
Cadherin-11 is highly expressed in rhabdomyosarcomas and during differentiation of myoblasts in vitro.
J Pathol
1999; 187: 164–172.
10.1002/(SICI)1096-9896(199901)187:2<164::AID-PATH208>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 69 Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW. Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 1999; 59: 947–952.
- 70 Pokutta S, Herrenknecht K, Kemler R, Engel J. Conformational changes of the recombinant extracellular domain of E-cadherin upon calcium binding. Eur J Biochem 1994; 223: 1019–1026.
- 71 Nose A, Tsuji K, Takeichi M. Localization of specificity determining sites in cadherin cell adhesion molecules. Cell 1990; 61: 147–155.
- 72 Tomschy A, Fauser C, Landwehr R, Engel J. Homophilic adhesion of E-cadherin occurs by a co-operative two-step interaction of N-terminal domains. EMBO J 1996; 15: 3507–3514.
- 73 Boggon TJ, Murray J, Chappuis-Flament S, Wong E, Gumbiner BM, Shapiro L. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 2002; 296: 1308–1313.
- 74 Perret E, et al. Fast dissociation kinetics between individual E-cadherin fragments revealed by flow chamber analysis. EMBO J 2002; 21: 2537–2546.
- 75 Tamura K, Shan WS, Hendrickson WA, Colman DR, Shapiro L. Structure-function analysis of cell adhesion by neural (N-) cadherin. Neuron 1998; 20: 1153–1163.
- 76 Brieher WM, Yap AS, Gumbiner BM. Lateral dimerization is required for the homophilic binding activity of C-cadherin. J Cell Biol 1996; 135: 487–496.
- 77 Yap AS, Brieher WM, Pruschy M, Gumbiner BM. Lateral clustering of the adhesive ectodomain: a fundamental determinant of cadherin function. Curr Biol 1997; 7: 308–315.
- 78 Takeda H, Shimoyama Y, Nagafuchi A, Hirohashi S. E-cadherin functions as a cis-dimer at the cell-cell adhesive interface in vivo. Nat Struct Biol 1999; 6: 310–312.
- 79 Tsuiji H, Xu L, Schwartz K, Gumbiner BM. Cadherin conformations associated with dimerization and adhesion. J Biol Chem 2007; 282: 12871–12882.
- 80 Zhang Y, Sivasankar S, Nelson WJ, Chu S. Resolving cadherin interactions and binding cooperativity at the single-molecule level. Proc Natl Acad Sci USA 2009; 106: 109–114.
- 81 Patel SD, et al. Type II cadherin ectodomain structures: implications for classical cadherin specificity. Cell 2006; 124: 1255–1268.
- 82 Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005; 6: 622–634.
- 83 Reynolds AB, Daniel J, McCrea PD, Wheelock MJ, Wu J, Zhang Z. Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mol Cell Biol 1994; 14: 8333–8342.
- 84 Daniel JM, Reynolds AB. The tyrosine kinase substrate p120cas binds directly to E-cadherin but not to the adenomatous polyposis coli protein or alpha-catenin. Mol Cell Biol 1995; 15: 4819–4824.
- 85 Shibamoto S, et al. Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes. J Cell Biol 1995; 128: 949–957.
- 86 Staddon JM, Smales C, Schulze C, Esch FS, Rubin LL. p120, a p120-related protein (p100), and the cadherin/catenin complex. J Cell Biol 1995; 130: 369–381.
- 87 Ireton RC, et al. A novel role for p120 catenin in E-cadherin function. J Cell Biol 2002; 159: 465–476.
- 88 Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J Cell Biol 2003; 163: 525–534.
- 89 Baki L, et al. Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex. Proc Natl Acad Sci USA 2001; 98: 2381–2386.
- 90 Fujita Y, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002; 4: 222–231.
- 91 Noren NK, Liu BP, Burridge K, Kreft B. p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J Cell Biol 2000; 150: 567–580.
- 92 Anastasiadis PZ, et al. Inhibition of RhoA by p120 catenin. Nat Cell Biol 2000; 2: 637–644.
- 93 Grosheva I, Shtutman M, Elbaum M, Bershadsky AD. p120 catenin affects cell motility via modulation of activity of Rho-family GTPases: a link between cell-cell contact formation and regulation of cell locomotion. J Cell Sci 2001; 114: 695–707.
- 94 Anastasiadis PZ, Reynolds AB. Regulation of Rho GTPases by p120-catenin. Curr Opin Cell Biol 2001; 13: 604–610.
- 95 Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989; 8: 1711–1717.
- 96 Jou TS, Stewart DB, Stappert J, Nelson WJ, Marrs JA. Genetic and biochemical dissection of protein linkages in the cadherin-catenin complex. Proc Natl Acad Sci USA 1995; 92: 5067–5071.
- 97 Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci USA 1995; 92: 8813–8817.
- 98 Kobielak A, Fuchs E. Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. Nat Rev Mol Cell Biol 2004; 5: 614–625.
- 99 Watabe-Uchida M, et al. alpha-Catenin-vinculin interaction functions to organize the apical junctional complex in epithelial cells. J Cell Biol 1998; 142: 847–857.
- 100 Knudsen KA, Soler AP, Johnson KR, Wheelock MJ. Interaction of alpha-actinin with the cadherin/catenin cell-cell adhesion complex via alpha-catenin. J Cell Biol 1995; 130: 67–77.
- 101 Itoh M, Nagafuchi A, Moroi S, Tsukita S. Involvement of ZO-1 in cadherin-based cell adhesion through its direct binding to alpha catenin and actin filaments. J Cell Biol 1997; 138: 181–192.
- 102 Yamada S, Pokutta S, Drees F, Weis WI, Nelson WJ. Deconstructing the cadherin-catenin-actin complex. Cell 2005; 123: 889–901.
- 103 Drees F, Pokutta S, Yamada S, Nelson WJ, Weis WI. Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell 2005; 123: 903–915.
- 104 Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002; 296: 1644–1646.
- 105 Kiener HP, Stipp CS, Allen PG, Higgins JM, Brenner MB. The cadherin-11 cytoplasmic juxtamembrane domain promotes alpha-catenin turnover at adherens junctions and intercellular motility. Mol Biol Cell 2006; 17: 2366–2376.
- 106 Kiener HP, Lee DM, Agarwal SK, Brenner MB. Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro. Am J Pathol 2006; 168: 1486–1499.
- 107 Lee DM, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315: 1006–1010.
- 108 Vandooren B, et al. Tumor necrosis factor alpha drives cadherin 11 expression in rheumatoid inflammation. Arthritis Rheum 2008; 58: 3051–3062.
- 109 Orlandini M, Oliviero S. In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by cadherin-11. J Biol Chem 2001; 276: 6576–6581.
- 110 McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev 2007; 7: 429–442.
- 111 Filer A, Pitzalis C, Buckley CD. Targeting the stromal microenvironment in chronic inflammation. Curr Opin Pharmacol 2006; 6: 393–400.
- 112 Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 2002; 46: 298–308.
- 113 Plows D, Kontogeorgos G, Kollias G. Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol 1999; 162: 1018–1023.
- 114 Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leuk Biol 2000; 67: 149–159.
- 115 Bromley M, Woolley DE. Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum 1984; 27: 857–863.
- 116 Scott BB, Weisbrot LM, Greenwood JD, Bogoch ER, Paige CJ, Keystone EC. Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation. Arthritis Rheum 1997; 40: 490–498.
- 117 Muller-Ladner U, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996; 149: 1607–1615.
- 118 Kiener HP, Niederreiter B, Lee DM, Jimenez-Boj E, Smolen JS, Brenner MB. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis Rheum 2009; 60: 1305–1310.
- 119 Vallin J, Girault JM, Thiery JP, Broders F. Xenopus cadherin-11 is expressed in different populations of migrating neural crest cells. Mech Dev 1998; 75: 171–174.
- 120 Kashef J, Kohler A, Kuriyama S, Alfandari D, Mayor R, Wedlich D. Cadherin-11 regulates protrusive activity in Xenopus cranial neural crest cells upstream of Trio and the small GTPases. Genes Dev 2009; 23: 1393–1398.
- 121 Feltes CM, Kudo A, Blaschuk O, Byers SW. An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res 2002; 62: 6688–6697.
- 122 Farina AK, Bong YS, Feltes CM, Byers SW. Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells. PLoS ONE 2009; 4: e4797.
- 123 Sato K, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993; 53: 851–856.
- 124 Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16: 249–284.
- 125 Nishimoto N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162–1167.
- 126 Emery P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516–1523.
- 127 Nishimoto N, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Modern Rheumatol 2009; 19: 12–19.
- 128 Smolen JS, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987–997.
Citing Literature
